Developing Consensus for a More Provider-Friendly Next Generation Sequencing Molecular Biomarker Report

A significant challenge to providing a provider-friendly (often referred to as “oncologist-friendly”) molecular biomarker report is effectively communicating the clinical significance of any specific biomarker variant, not only in the context of a particular patient’s disease, but also in relation to other identified variants and the current level of evidence supporting variant impact on pathogenicity. Believing adoption of more provider-friendly report formats can provide better diagnostic guidance, AMP formed a multidisciplinary working group with representation from American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP). Public comment periods provided international interest holder input and helped identify areas of consensus. The provider-friendly template provides guidance on structuring elements that should be present for any solid tissue cancer molecular biomarker report, using non-small cell lung cancer as a pilot. Pre- and post-webinar surveys will be conducted, and December 2025 – 2026 attendees (live and on-demand) will be resurveyed in 1 year to evaluate implementation of the reporting template and/or concepts. This project was supported by an unrestricted continuing medical education grant from AstraZeneca and Daiichi Sankyo, Inc.

To register, visit the Association for Molecular Pathology.